Zacks Investment Research on MSN2 天
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
Shares of Puma Biotechnology PBYI have rallied 35.3% in the past six months against the industry’s decline of 9.2%. The ...
Business Wire17 天
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical ...
Morningstar24 天
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical ...
Sneaker Fortress on MSN4 个月
The PUMA Inhale Returns: A Blast from the Past or Just a Tired Rehash?
The PUMA Inhale sneaker belongs to the Cellerator family, which features the brand’s signature CELL cushioning technology.
Le Lézard16 天
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCAtm-Lung1, a Phase II clinical trial ...